Buljubasic Fanis, El-Battrawy Ibrahim, Lan Huan, Lomada Santosh K, Chatterjee Anupriya, Zhao Zhihan, Li Xin, Zhong Rujia, Xu Qiang, Huang Mengying, Liao Zhenxing, Lang Siegfried, Cyganek Lukas, Zhou Xiaobo, Wieland Thomas, Borggrefe Martin, Akin Ibrahim
First Department of Medicine, Medical Faculty Mannheim, University Medical Centre Mannheim, University of Heidelberg, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany.
DZHK (German Center for Cardiovascular Research), Partner Sites, Heidelberg-Mannheim and Göttingen, 68167 Mannheim, Germany.
J Clin Med. 2020 Feb 10;9(2):486. doi: 10.3390/jcm9020486.
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a rare, inheritable cardiac disorder characterized by ventricular tachyarrhythmias, progressive loss of cardiomyocytes with fibrofatty replacement and sudden cardiac death. The exact underlying mechanisms are unclear.
This study investigated the possible roles of nucleoside diphosphate kinase B (NDPK-B) and SK4 channels in the arrhythmogenesis of ARVC by using human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
In hiPSC-CMs from a patient with ARVC, the expression levels of NDPK-B and SK4 channels were upregulated, the cell automaticity was increased and the occurrence rate of arrhythmic events was enhanced. Recombinant NDPK-B applied into hiPSC-CMs from either healthy donors or the patient enhanced SK4 channel current (I), cell automaticity and the occurrence of arrhythmic events, whereas protein histidine phosphatase 1 (PHP-1), a counter actor of NDPK-B, prevented the NDPK-B effect. Application of PHP-1 alone or a SK4 channel blocker also reduced cell automaticity and arrhythmic events.
This study demonstrated that the elevated NDPK-B expression, via activating SK4 channels, contributes to arrhythmogenesis in ARVC, and hence, NDPK-B may be a potential therapeutic target for treating arrhythmias in patients with ARVC.
致心律失常性右室心肌病(ARVC)是一种罕见的遗传性心脏疾病,其特征为室性快速心律失常、心肌细胞进行性丧失伴纤维脂肪替代以及心源性猝死。确切的潜在机制尚不清楚。
本研究通过使用人诱导多能干细胞衍生的心肌细胞(hiPSC-CMs),研究核苷二磷酸激酶B(NDPK-B)和SK4通道在ARVC心律失常发生中的可能作用。
在一名ARVC患者的hiPSC-CMs中,NDPK-B和SK4通道的表达水平上调,细胞自律性增加,心律失常事件的发生率提高。将重组NDPK-B应用于来自健康供体或该患者的hiPSC-CMs中,可增强SK4通道电流(I)、细胞自律性和心律失常事件的发生,而NDPK-B的拮抗因子蛋白组氨酸磷酸酶1(PHP-1)可阻止NDPK-B的作用。单独应用PHP-1或SK4通道阻滞剂也可降低细胞自律性和心律失常事件。
本研究表明,NDPK-B表达升高通过激活SK4通道,促进ARVC心律失常的发生,因此,NDPK-B可能是治疗ARVC患者心律失常的潜在治疗靶点。